107 related articles for article (PubMed ID: 31727181)
1. Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus.
Okada J; Yamada E; Niijima Y; Okada S; Yamada M
J Health Popul Nutr; 2019 Nov; 38(1):33. PubMed ID: 31727181
[TBL] [Abstract][Full Text] [Related]
2. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
Lando HM; Alattar M; Dua AP
Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
5. The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
Rai P; Zhao X; Sambamoorthi U
J Pain Palliat Care Pharmacother; 2018; 32(2-3):90-97. PubMed ID: 30676844
[TBL] [Abstract][Full Text] [Related]
6. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy.
Araújo F; Shrestha N; Gomes MJ; Herranz-Blanco B; Liu D; Hirvonen JJ; Granja PL; Santos HA; Sarmento B
Nanoscale; 2016 May; 8(20):10706-13. PubMed ID: 27150301
[TBL] [Abstract][Full Text] [Related]
7. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
8. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
Hegedüs L; Moses AC; Zdravkovic M; Le Thi T; Daniels GH
J Clin Endocrinol Metab; 2011 Mar; 96(3):853-60. PubMed ID: 21209033
[TBL] [Abstract][Full Text] [Related]
10. Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities.
Cakmak R; Caklili OT; Tekin S; Hacisahinogullari H; Tanrikulu S; Koc MS; Dinccag N
Biomark Med; 2022 Jan; 16(1):5-10. PubMed ID: 34856813
[No Abstract] [Full Text] [Related]
11. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
[TBL] [Abstract][Full Text] [Related]
12. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
13. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Ahrén B
Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
[TBL] [Abstract][Full Text] [Related]
14. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes.
Dalle S; Burcelin R; Gourdy P
Cell Signal; 2013 Feb; 25(2):570-9. PubMed ID: 23159576
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery.
Briere DA; Bueno AB; Gunn EJ; Michael MD; Sloop KW
Diabetes; 2018 Feb; 67(2):309-320. PubMed ID: 29203510
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
17. LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
Steinberg WM; Nauck MA; Zinman B; Daniels GH; Bergenstal RM; Mann JF; Steen Ravn L; Moses AC; Stockner M; Baeres FM; Marso SP; Buse JB;
Pancreas; 2014 Nov; 43(8):1223-31. PubMed ID: 25275271
[TBL] [Abstract][Full Text] [Related]
18. Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.
Gustavson SM; Dai H; Preston GM; Somayaji V; Hirshberg B; Calle RA
Diabetes Res Clin Pract; 2011 Feb; 91(2):e45-9. PubMed ID: 21130513
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
